Niño-Ramírez Jairo Eduardo, Gil-Etayo Francisco Javier, Fonseca-Santos Marta, López-Pérez Juan, Jiménez Hernaz Isabel, Vicente Parra Ariadna, Terradillos Sánchez Pilar, Calzada Nuria, Boix Francisco, Marín Luis, Arroyo-Sánchez Daniel, Alcoceba Miguel, Navarro-Bailón Almudena, Peña-Muñoz Felipe, Marcos Asensio Sara, Pérez-López Estefanía, Vázquez Lourdes, Sánchez-Guijo Fermín, García-Sanz Ramón, López-Corral Lucía, Tejeda Velarde Amalia
Servicio de Hematología, Hospital Universitario de Salamanca, Salamanca, Spain.
Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain.
HLA. 2025 Aug;106(2):e70340. doi: 10.1111/tan.70340.
Haploidentical haematopoietic stem-cell transplantation (haplo-HSCT) is characterised by a high degree of HLA mismatching. Therefore, NK alloreactivity driven by the interactions between KIR and HLA mismatched molecules could benefit its outcome. However, the influence of NK alloreactivity in haplo-HSCT with post-transplant Cyclophosphamide (PTCy) remains controversial. The aim of this work was to investigate the clinical utility of predicting NK alloreactivity according to previously described models in the context of haplo-HSCT with PTCy. We studied 145 patients who underwent this procedure, evaluating the influence of NK alloreactivity in transplant outcomes. Models that disregard the interactions between KIR and HLA evidenced an unsuccessful prediction of the outcomes. On the contrary, approaches based on KIR-HLA interaction were the most accurate to predict transplant outcomes. The analysis of inhibitory KIRs (iKIRs) based on the missing-ligand model showed that the presence of at least two iKIR mismatches (iKIRmm) among the donor-recipient pair was an independent risk factor for acute graft-versus-host disease (aGvHD) grade III‑IV (HR: 3.21, p = 0.021), relapse rate (HR: 2.46, p = 0.046), relapse-free survival (RFS) (HR: 1.96, p = 0.039) and GvHD/relapse-free survival (GRFS) (HR = 2.16, p = 0.008). The analysis of the missing-licensing model showed that the existence of the mismatch KIR2DL1/C2 associated to relapse rate (HR: 4.34, p = 0.002) and more than one iKIRmm correlated to poorer RFS (HR: 2.31, p = 0.038) and GRFS (HR: 2.26, p = 0.022). These results suggest that NK alloreactivity influences the outcome of haplo-HSCT with PTCy and should be incorporated into the donor selection algorithm for this procedure.
单倍型相合造血干细胞移植(haplo-HSCT)的特点是高度的HLA错配。因此,由KIR与HLA错配分子之间的相互作用驱动的NK细胞同种异体反应性可能有益于其治疗结果。然而,NK细胞同种异体反应性在接受移植后环磷酰胺(PTCy)的haplo-HSCT中的影响仍存在争议。这项工作的目的是在接受PTCy的haplo-HSCT背景下,根据先前描述的模型研究预测NK细胞同种异体反应性的临床效用。我们研究了145例接受该手术的患者,评估了NK细胞同种异体反应性对移植结果的影响。忽略KIR与HLA之间相互作用的模型对结果的预测未成功。相反,基于KIR-HLA相互作用的方法对移植结果的预测最为准确。基于缺失配体模型对抑制性KIR(iKIR)的分析表明,供体-受体对中至少存在两个iKIR错配(iKIRmm)是急性移植物抗宿主病(aGvHD)III-IV级(HR:3.21,p = 0.)的独立危险因素。021)、复发率(HR:2.46,p = 0.046)、无复发生存期(RFS)(HR:1.96,p = 0.039)和无GvHD/复发生存期(GRFS)(HR = 2.16,p = 0.008)。缺失许可模型的分析表明,错配KIR2DL1/C2的存在与复发率相关(HR:4.34,p = 0.002),并且一个以上的iKIRmm与较差的RFS(HR:2.31,p = 0.038)和GRFS(HR:2.26,p = 0.022)相关。这些结果表明,NK细胞同种异体反应性影响接受PTCy的haplo-HSCT的结果,应将其纳入该手术的供体选择算法中。